Cefoxitin: Interesting Perspectives on a Neglected Intravenous Beta-lactam
PDF
Cite
Share
Request
RESEARCH ARTICLE
VOLUME: 7 ISSUE: 1
P: 36 - 36
January 2018

Cefoxitin: Interesting Perspectives on a Neglected Intravenous Beta-lactam

Mediterr J Infect Microb Antimicrob 2018;7(1):36-36
1. Service de Maladies Infectieuses, Hôpital de Mercy, Centre Hospitalier Régional Metz-Thionville, Ars-Laquenexy, France
2. Université Claude Bernard Lyon 1, Lyon, France
3. Service de Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
4. Laboratoire de Bactériologie, Institut des Agents Infectieux, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
5. Service de Réanimation Médicale, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France
6. Centre International de Recherche en Infectiologie, Lyon, France
No information available.
No information available
Received Date: 18.06.2018
Accepted Date: 27.11.2018
PDF
Cite
Share
Request

Abstract

Cefoxitin is a beta-lactam antibiotic belonging to the cephamycins class, up to now only used in clinical practice for prophylaxis during surgery. Recently, its use has increased due to the spread of infections caused by extended-spectrum beta-lactamase-producing bacteria, particularly urinary tract infections. It has a broad antimicrobial spectrum and is also effective in polymicrobial bone and joint infections or skin and soft tissue infections. Stability data allows its use as a continuous infusion in intensive care units or with elastomeric diffuser for outpatients. Cefoxitin is well tolerated. The aim of this article was to highlight the interesting aspects of this old and inexpensive intravenous beta-lactam.

Keywords:
Cephamycins, osteomyelitis, extended-spectrum beta-lactamase, continuous infusion, infection